JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sprague, J. E.
Right arrow Articles by Anderson, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sprague, J. E.
Right arrow Articles by Anderson, C. J.
Journal of Nuclear Medicine Vol. 48 No. 2 311-318
© 2007 by Society of Nuclear Medicine

Basic Science Investigation

Noninvasive Imaging of Osteoclasts in Parathyroid Hormone–Induced Osteolysis Using a 64Cu-Labeled RGD Peptide

Jennifer E. Sprague1, Hideki Kitaura2, Wei Zou2, Yunpeng Ye1, Samuel Achilefu1, Katherine N. Weilbaecher3, Steven L. Teitelbaum2 and Carolyn J. Anderson1

1 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; 2 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri; and 3 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

Correspondence: For correspondence or reprints contact: Carolyn J. Anderson, PhD, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd., Campus Box 8225, St. Louis, MO 63110. E-mail: andersoncj{at}wustl.edu

Bone diseases are often a result of increased numbers of osteoclasts, or bone-resorbing cells. Bone metastases are a significant cause of morbidity in many types of cancer. An imaging agent targeting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in patients with osteolytic or mixed bone metastases. Osteoclasts express high levels of {alpha}vß3 integrin, to which peptides containing the Arg-Gly-Asp (RGD) sequence are known to bind. We proposed that radiolabeled RGD peptides could be used to detect osteoclasts in lytic bone lesions. Methods: The cross-bridged macrocyclic chelator 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) was conjugated to c(RGDyK) for radiolabeling with 64Cu (t1/2, 12.7 h; ß+, 17.4%; Eß+max, 656 keV; ß–, 39%; Eß–max, 573 keV). The in vitro affinity of Cu(II)-CB-TE2A-c(RGDyK) for {alpha}vß3 and {alpha}vß5 was evaluated in a heterologous competitive binding assay. Ex vivo uptake was examined in osteoclasts prepared from bone marrow macrophages. As a proof of principle, biodistribution and imaging studies were performed on parathyroid hormone (PTH)–induced osteolysis in the calvarium. Results: Cu-CB-TE2A-c(RGDyK) was shown to have a 30-fold higher affinity for {alpha}vß3 than for {alpha}vß5. Osteoclasts were shown to specifically take up 64Cu-CB-TE2A-c(RGDyK). However, bone marrow macrophages showed only nonspecific uptake. PTH treatment increased calvarial uptake of 64Cu-CB-TE2A-c(RGDyK), compared with uptake in mice receiving a sham treatment. In addition, calvarial uptake correlated linearly with the number of osteoclasts on the bone surface. Conclusion: These results suggest that 64Cu-CB-TE2A-c(RGDyK) selectively binds {alpha}vß3 on osteoclasts and may potentially be used to identify increased numbers of osteoclasts in osteolytic bone diseases such as osteolytic bone metastasis and inflammatory osteolysis.

Key Words: bone • PET/CT • radiopharmaceuticals • copper-64 • integrin • osteoclast

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.